GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE331nnn/GSE331378/primaryOK200Transcriptomics Mus musculusHomo sapiensExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE331378GEOGSEfalseBulk RNA-seq of PC3-derived human prostate cancer xenografts and matched mouse blood following treatment with the bivalent BET bromodomain inhibitor MS645 or the monovalent inhibitor JQ1Male ICR SCID mice (5-6 weeks old) were implanted subcutaneously with 5 x 10^6 PC3 cells. When tumors reached ~200 mm^3, mice were randomized to one of three treatment arms: vehicle, JQ1 (30 mg/kg), or MS645 (20 mg/kg). Compounds were administered intraperitoneally. At study end, mice were sacrificed and matched xenograft tumor and whole-blood specimens were collected and snap-frozen for bulk RNA-seq. Tumor RNA-seq reads were aligned to the human reference genome (GRCh38/hg38) and blood RNA-seq reads to the mouse reference genome (GRCm38/mm10). Differential expression analysis (DESeq2) was used to compare MS645 vs vehicle and JQ1 vs vehicle in each compartment. The study identifies the BRD4-RUVBL1/2 axis as a mediator of intrinsic resistance to monovalent BET bromodomain inhibition in AR-negative prostate cancer and demonstrates that bivalent BET targeting by MS645 reprograms resistant tumors toward a treatment-responsive transcriptional state.2026/08/29GSE331378GSM9744945GSM9744934GSM9744944GSM9744933GSM9744943GSM9744932GSM9744931GSM9744942GSM9744938GSM9744949GSM9744948GSM9744937GSM9744947GSM9744936GSM9744946GSM9744935GSM9744941GSM9744952GSM9744951GSM9744940GSM9744950GSM97449393428134328331378 Mus musculusHomo sapiens